The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity
Abstract
Context: Hypothalamic obesity is a rare, treatment-resistant form of obesity. In preliminary studies, the hypothalamic hormone oxytocin (OXT) has shown promise as a potential weight loss therapy. Objective: To determine whether 8 weeks of intranasal OXT (vs 8 weeks of placebo) promotes weight loss in children, adolescents, and young adults with hypothalamic obesity. Methods: This randomized, double-blind, placebo-controlled, crossover pilot trial (NCT02849743), conducted at an outpatient academic medical center, included patients aged 10 to 35 years with hypothalamic obesity from hypothalamic/pituitary tumors. Participants received intranasal OXT (Syntocinon, 40 USP units/mL, 4 IU/spray) vs excipient-matched placebo, 16 to 24 IU 3 times daily at mealtimes. Weight loss attributable to OXT vs placebo and safety (adverse events) were assessed. Results: Of 13 individuals randomized (54% female, 31% pre-pubertal, median age 15.3 years, IQR 13.3-20.6), 10 completed the entire study. We observed a nonsignificant within-subject weight change of −0.6 kg (95% CI: −2.7, 1.5) attributable to OXT vs placebo. A subset (2/18 screened, 5/13 randomized) had prolonged QTc interval on electrocardiography prior to screening and/or in both treatment conditions. Overall, OXT was well-tolerated, and adverse events (epistaxis and nasal irritation, headache, nausea/vomiting, and changes in heart rate, blood pressure, and QTc interval) were similar between OXT and placebo. In exploratory analyses, benefits of OXT for anxiety and impulsivity were observed. Conclusion: In this pilot study in hypothalamic obesity, we did not detect a significant impact of intranasal OXT on body weight. OXT was well-tolerated, so future larger studies could examine different dosing, combination therapies, and potential psychosocial benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As oxytocin may be lowered or deficient, a pilot randomized trial was conducted to investigate its effect on behavior. Some benefits of oxytocin for anxiety and impulsivity were observed, but it did not improve obesity in individuals with hypothalamic obesity (159).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anthropometric Standardization Reference Manual
Lohman, T. J., Roache, A. F., & Martorell, R. (1992) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-199208000-00020 · Cited by 2,764 · cited 1×
“All measurements follow the methods described in The Anthropometric Standardization Manual of Lohman et al [28].”
MethodOn the ability to inhibit simple and choice reaction time responses: A model and a method.
Logan, G. D., Cowan, W. B., & Davis, K. A. (1984) · Journal of Experimental Psychology: Human Perception and Performance · doi:10.1037/0096-1523.10.2.276 · Cited by 1,542
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research
MacDonald, E., Dadds, M. R., Brennan, J. L., Williams, K., Levy, F., & Cauchi, A. J. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.02.015 · Cited by 359
Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.162 · Cited by 344
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Sikich, L., Kolevzon, A., King, B. H., McDougle, C. J., Sanders, K. B., Kim, S.-J., Spanos, M., Chandrasekhar, T., Trelles, M. D. P., Rockhill, C. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103583 · Cited by 298 · cited 1×
“Also, as a recent negative study of OXT in autism illustrates, selection of the most appropriate participants and OXT-sensitive outcomes is essential [70].”
BackgroundValstad, M., Alvares, G. A., Egknud, M., Matziorinis, A. M., Andreassen, O. A., Westlye, L. T., & Quintana, D. S. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.017 · Cited by 277 · cited 1×
“Moreover, peripheral OXT concentrations may not reflect tissue concentrations in the most relevant target tissues, such as the brain [57, 58].”
BackgroundMeasuring Oxytocin and Vasopressin: Bioassays, Immunoassays and Random Numbers
Leng, G., & Sabatier, N. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12413 · Cited by 237 · cited 3×
“Diastolic BP, mm Hg 62 [56, 64] 58 [57, 65] 60 [55, 64]”
BackgroundA Cortical Circuit for Sexually Dimorphic Oxytocin-Dependent Anxiety Behaviors
Li, K., Nakajima, M., Ibañez-Tallon, I., & Heintz, N. (2016) · Cell · doi:10.1016/j.cell.2016.08.067 · Cited by 234
Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models
Zhang, H., Wu, C., Chen, Q., Chen, X., Xu, Z., Wu, J., & Cai, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061477 · Cited by 224
Research works printed but not linked: 53
- Muller, 2020, Management of hypothalamic obesity, Endocrinol Metab Clin North Am, 49, 533, 10.1016/j.ecl.2020.05.009 · DOI
- Madsen, 2019, Endoscopic endonasal resection versus open surgery for pediatric craniopharyngioma: comparison of outcomes and complications, J Neurosurg Pediatr, 24, 236, 10.3171/2019.4.PEDS18612 · DOI
- Shaikh, 2008, Reductions in basal metabolic rate and physical activity contribute to hypothalamic obesity, J Clin Endocrinol Metab, 93, 2588, 10.1210/jc.2007-2672 · DOI
- Cohen, 2013, Autonomic nervous system balance in children and adolescents with craniopharyngioma and hypothalamic obesity, Eur J Endocrinol, 168, 845, 10.1530/EJE-12-1082 · DOI
- Roth, 1998, Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite, Eur J Endocrinol, 138, 89, 10.1530/eje.0.1380089 · DOI · Paper page
- Olsson, 2015, Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden, J Clin Endocrinol Metab, 100, 467, 10.1210/jc.2014-3525 · DOI · Paper page
- Jung, 2017, Nonalcoholic fatty liver disease in long-term survivors of childhood-onset craniopharyngioma, Ann Pediatr Endocrinol Metab, 22, 189, 10.6065/apem.2017.22.3.189 · DOI
- Yuen, 2018, Relative risks of contributing factors to morbidity and mortality in adults with craniopharyngioma on growth hormone replacement, J Clin Endocrinol Metab, 103, 768, 10.1210/jc.2017-01542 · DOI
- Qiao, 2019, Excess mortality after craniopharyngioma treatment: are we making progress?, Endocrine, 64, 31, 10.1007/s12020-018-1830-y · DOI
- Rose, 2018, Hypothalamic obesity: 4 years of the international registry of hypothalamic obesity disorders, Obesity (Silver Spring), 26, 1727, 10.1002/oby.22315 · DOI
- van Iersel, 2019, Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review, Endocr Rev, 40, 193, 10.1210/er.2018-00017 · DOI · Paper page
- McCormack, 2020, Metabolic effects of oxytocin, Endocr Rev, 41, 121, 10.1210/endrev/bnz012 · DOI
- Daubenbuchel, 2016, Oxytocin in survivors of childhood-onset craniopharyngioma, Endocrine, 54, 524, 10.1007/s12020-016-1084-5 · DOI · Paper page
- Hsu, 2018, Oxytocin and naltrexone successfully treat hypothalamic obesity in a boy post-craniopharyngioma resection, J Clin Endocrinol Metab, 103, 370, 10.1210/jc.2017-02080 · DOI
- Lustig, 2003, Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial, J Clin Endocrinol Metab, 88, 2586, 10.1210/jc.2002-030003 · DOI · Paper page
- Liu, 2020, Sex differences and estrous influences on oxytocin control of food intake, Neuroscience, 447, 63, 10.1016/j.neuroscience.2019.10.020 · DOI
- Blevins, 2015, Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys, Am J Physiol Regul Integr Comp Physiol, 308, R431, 10.1152/ajpregu.00441.2014 · DOI · Paper page
- Kuczmarski, 2000, CDC Growth charts: United States, Adv Data, 1
- Plessow, 2021, Oxytocin administration increases proactive control in men with overweight or obesity: a randomized, double-blind, placebo-controlled crossover study, Obesity (Silver Spring), 29, 56, 10.1002/oby.23010 · DOI
- Bartholdy, 2016, A systematic review of the relationship between eating, weight and inhibitory control using the stop signal task, Neurosci Biobehav Rev, 64, 35, 10.1016/j.neubiorev.2016.02.010 · DOI · Paper page
- Logan, 2014, On the ability to inhibit thought and action: general and special theories of an act of control, Psychol Rev, 121, 66, 10.1037/a0035230 · DOI · Paper page
- Dykens, 2007, Assessment of hyperphagia in Prader-Willi syndrome, Obesity (Silver Spring, Md), 15, 1816, 10.1038/oby.2007.216 · DOI · Paper page
- Stunkard, 1985, The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger, J Psychosom Res, 29, 71, 10.1016/0022-3999(85)90010-8 · DOI · Paper page
- Zemel, 2010, Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children, J Clin Endocrinol Metab, 95, 1265, 10.1210/jc.2009-2057 · DOI · Paper page
- Epstein, 1983, The McMaster family assessment device, J Marital Family Therapy, 9, 171, 10.1111/j.1752-0606.1983.tb01497.x · DOI · Paper page
- Greenhill, 2004, Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology, J Am Acad Child Adolesc Psychiatry, 43, 1488, 10.1097/01.chi.0000142668.29191.13 · DOI
- Hocking, 2015, Family functioning mediates the association between neurocognitive functioning and health-related quality of life in young adult survivors of childhood brain tumors, J Adolesc Young Adult Oncol, 4, 18, 10.1089/jayao.2014.0022 · DOI
- Mong, 2008, Cardiac risk after craniopharyngioma therapy, Pediatric Neurol, 38, 256, 10.1016/j.pediatrneurol.2007.11.007 · DOI · Paper page
- Muller, 2011, Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up, Eur J Endocrinol, 165, 17, 10.1530/EJE-11-0158 · DOI · Paper page
- Anekonda, 2021, Hindbrain administration of oxytocin reduces food intake, weight gain and activates catecholamine neurons in the hindbrain nucleus of the solitary tract in rats, J Clin Med, 10, 5078, 10.3390/jcm10215078 · DOI
- Alaerts, 2021, Changes in endogenous oxytocin levels after intranasal oxytocin treatment in adult men with autism: an exploratory study with long-term follow-up, Eur Neuropsychopharmacol, 43, 147, 10.1016/j.euroneuro.2020.11.014 · DOI
- Blevins, 2015, Translational and therapeutic potential of oxytocin as an anti-obesity strategy: insights from rodents, nonhuman primates and humans, Physiol Behav, 152, 438, 10.1016/j.physbeh.2015.05.023 · DOI
- Kou, 2021, In the nose or on the tongue? Contrasting motivational effects of oral and intranasal oxytocin on arousal and reward during social processing, Transl Psychiatry, 11, 94, 10.1038/s41398-021-01241-w · DOI
- Lee, 2018, Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay, Mol Psychiatry, 23, 115, 10.1038/mp.2017.27 · DOI · Paper page
- Ishii, 2021, Cerebral and extracerebral distribution of radioactivity associated with oxytocin in rabbits after intranasal administration: comparison of TTA-121, a newly developed oxytocin formulation, with syntocinon, PloS one, 16, 10.1371/journal.pone.0261451 · DOI
- Dykens, 2018, Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome, JCI Insight, 3, 10.1172/jci.insight.98333 · DOI
- Vankrieken, 1983, Oxytocin determination by radioimmunoassay, Gynecol Obstet Invest, 16, 180, 10.1159/000299248 · DOI
- Geschwind, 2021, Oxytocin for autism spectrum disorder - down, but not out, N Engl J Med, 385, 1524, 10.1056/NEJMe2110158 · DOI
- Damen, 2021, Oxytocin in young children with Prader-Willi syndrome: results of a randomized, double-blind, placebo-controlled, crossover trial investigating 3 months of oxytocin, Clin Endocrinol (Oxf), 94, 774, 10.1111/cen.14387 · DOI
- Hollander, 2021, Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi syndrome: a randomized controlled pilot trial, J Psychiatr Res, 137, 643, 10.1016/j.jpsychires.2020.11.006 · DOI
- Hoffmann, 2015, Eating behavior, weight problems and eating disorders in 101 long-term survivors of childhood-onset craniopharyngioma, J Pediatr Endocrinol Metab, 28, 35, 10.1515/jpem-2014-0415 · DOI
- Bishop-Gilyard, 2011, Weight reduction in obese adolescents with and without binge eating, Obesity (Silver Spring), 19, 982, 10.1038/oby.2010.249 · DOI
- Daughters, 2017, Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability, Endocrine, 57, 166, 10.1007/s12020-017-1332-3 · DOI
- Aulinas, 2019, Low plasma oxytocin levels and increased psychopathology in hypopituitary men with diabetes insipidus, J Clin Endocrinol Metab, 104, 3181, 10.1210/jc.2018-02608 · DOI
- Eisenberg, 2019, Oxytocin alterations and neurocognitive domains in patients with hypopituitarism, Pituitary, 22, 105, 10.1007/s11102-019-00936-0 · DOI
- Hoffmann, 2017, First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma, Endocrine, 56, 175, 10.1007/s12020-017-1257-x · DOI · Paper page
- Roth, 2021, A phase 3 randomized clinical trial using once-weekly GLP-1 receptor agonist in adolescents and young adults with hypothalamic obesity, Diabetes Obes Metab, 23, 363, 10.1111/dom.14224 · DOI · Paper page
- Altszuler, 1981, Intranasal instillation of oxytocin increases insulin and glucagon secretion, Proc Soc Exp Biol Med, 168, 123, 10.3181/00379727-168-41245 · DOI · Paper page
- Chiodera, 1984, Effect of pharmacological doses of oxytocin on insulin response to glucose in normal man, Hormone Res, 20, 150, 10.1159/000179988 · DOI
- Brede, 2019, Intranasal oxytocin fails to acutely improve glucose metabolism in obese men, Diabetes Obes Metab, 21, 424, 10.1111/dom.13527 · DOI
- Acosta, 2021, Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic, Obesity (Silver Spring), 29, 662, 10.1002/oby.23120 · DOI · Paper page
- Edwards, 2021, Effects of combined oxytocin and beta-3 receptor agonist (CL 316243) treatment on body weight and adiposity in male diet-induced obese rats, Front Physiol, 12, 10.3389/fphys.2021.725912 · DOI
- Kakouri, 2021, New incretin combination treatments under investigation in obesity and metabolism: a systematic review, Pharmaceuticals (Basel), 14, 869, 10.3390/ph14090869 · DOI
Cited by
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
Self-citationTreatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25
van Santen, H. M., & Müller, H. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf025 · Cited by 21
Metadata
- Authors
- McCormack, S. E., Wang, Z., Wade, K. L., Dedio, A., Cilenti, N., Crowley, J., Plessow, F., Bamba, V., Roizen, J. D., Jiang, Y., Stylli, J., Ramakrishnan, A., Platt, M. L., Shekdar, K., Fisher, M. J., Vetter, V. L., Hocking, M., Xiao, R., & Lawson, E. A.
- Affiliations
- Division of Endocrinology & Diabetes, Children's Hospital of Philadelphia , Philadelphia, PA 19104 , USA
- Biostatistics & Data Management, Children's Hospital of Philadelphia , Philadelphia, PA 19104 , USA
- Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 , USA
- Department of Psychology, School of Arts and Sciences, University of Pennsylvania , Philadelphia, PA 19104 , USA
- Georgetown University School of Medicine , Washington, DC 20007 , USA
- Department of Biological Sciences and Bioengineering, Indian Institute of Technology , Kanpur, Uttar Pradesh 208016 , India
- Division of Neuroradiology, Children's Hospital of Philadelphia , Philadelphia, PA 19104 , USA
- Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania , Philadelphia, PA 19104 , USA
- Center for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia , Philadelphia, PA 19104 , USA
- Center of Clinical Epidemiology & Biostatistics, Perelman School of Medicine at the University of Pennsylvania , Philadelphia, PA 19104 , USA
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2023-03-06
- Volume
- 7
- Issue
- 5
- ISSN
- 2472-1972
- Cited by
- 37
- References
- 22
- Language
- en
- Funders
- Doris Duke Clinical Scientist Development Award
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity. https://app.cochat.ai/papers/10.1210/jendso/bvad037
- The paper
- McCormack, S. E., Wang, Z., Wade, K. L., Dedio, A., Cilenti, N., Crowley, J., Plessow, F., Bamba, V., Roizen, J. D., Jiang, Y., Stylli, J., Ramakrishnan, A., Platt, M. L., Shekdar, K., Fisher, M. J., Vetter, V. L., Hocking, M., Xiao, R., & Lawson, E. A. (2023). A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity. Journal of the Endocrine Society. https://doi.org/10.1210/jendso/bvad037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.